<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>297</serviceExecutionTime><Drug id="80329"><DrugName>botulinum toxin A (intramuscular, blepharospasm/prosopospasm/strabismus/chronic migraine), Lanzhou Institute of Biological Products</DrugName><DrugNamesKey><Name id="43047032">HengLi</Name></DrugNamesKey><DrugSynonyms><Name><Value>botulinum toxin A (intramuscular, blepharospasm/prosopospasm/strabismus/chronic migraine), Lanzhou Institute of Biological Products</Value></Name><Name><Value>HengLi</Value><Types><Type>Trade Name</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1061250">Lanzhou Institute of Biological Products</CompanyOriginator><CompaniesPrimary><Company id="1061250">Lanzhou Institute of Biological Products</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1061250" type="Company"><TargetEntity id="5035561640" type="organizationId">Lanzhou Institute of Biological Products Co Ltd</TargetEntity></SourceEntity><SourceEntity id="210" type="ciIndication"><TargetEntity id="G43" type="ICD10"></TargetEntity><TargetEntity id="10027599" type="MEDDRA"></TargetEntity><TargetEntity id="D008881" type="MeSH"></TargetEntity><TargetEntity id="-672899670" type="omicsDisease"></TargetEntity><TargetEntity id="27" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2239" type="ciIndication"><TargetEntity id="G24.5" type="ICD10"></TargetEntity><TargetEntity id="333.81" type="ICD9"></TargetEntity><TargetEntity id="10005159" type="MEDDRA"></TargetEntity><TargetEntity id="D001764" type="MeSH"></TargetEntity><TargetEntity id="-835604233" type="omicsDisease"></TargetEntity><TargetEntity id="759" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2481" type="ciIndication"><TargetEntity id="10042159" type="MEDDRA"></TargetEntity><TargetEntity id="D013285" type="MeSH"></TargetEntity><TargetEntity id="-1449503512" type="omicsDisease"></TargetEntity><TargetEntity id="3125" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="358" type="ciIndication"><TargetEntity id="M62.83" type="ICD10"></TargetEntity><TargetEntity id="10028334" type="MEDDRA"></TargetEntity><TargetEntity id="D013035" type="MeSH"></TargetEntity><TargetEntity id="-323136046" type="omicsDisease"></TargetEntity><TargetEntity id="154" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="913" type="ciIndication"><TargetEntity id="10028335" type="MEDDRA"></TargetEntity><TargetEntity id="D009122" type="MeSH"></TargetEntity><TargetEntity id="-702772965" type="omicsDisease"></TargetEntity><TargetEntity id="175" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Blepharospasm - China - Dec-1997</FirstLaunched><FirstLaunched>Muscle spasm - China - Dec-1997</FirstLaunched><FirstLaunched>Strabismus - China - Dec-1997</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="210">Migraine</Indication><Indication id="2239">Blepharospasm</Indication><Indication id="2481">Strabismus</Indication><Indication id="358">Muscle spasm</Indication><Indication id="913">Muscle hypertonia</Indication></IndicationsPrimary><ActionsPrimary><Action id="162">Acetylcholine receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2946">Analgesic</Action><Action id="450">Neuromuscular blocking agent</Action></ActionsSecondary><Technologies><Technology id="93">Toxin</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N2C</Code><Name>ANTI-MIGRAINE PREPARATIONS</Name></Ephmra><Ephmra><Code>M3A</Code><Name>MUSCLE RELAXANTS, PERIPHERALLY ACTING</Name></Ephmra><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-07-10T05:02:25.000Z</LastModificationDate><ChangeDateLast>2016-11-03T00:00:00.000Z</ChangeDateLast><AddedDate>2012-08-23T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1061250" linkType="Company"&gt;Lanzhou Institute of Biological Products&lt;/ulink&gt; has developed and launched botulinum toxin A (HengLi) for the im treatment of blepharospasm, prosopospasm and strabismus. It was assumed that the drug was launched in China shortly after its approval there in 1997 [&lt;ulink linkID="1317187" linkType="Reference"&gt;1317187&lt;/ulink&gt;], [&lt;ulink linkID="1312309" linkType="Reference"&gt;1312309&lt;/ulink&gt;], [&lt;ulink linkID="1613933" linkType="Reference"&gt;1613933&lt;/ulink&gt;]. The institute is also developing the drug for the potential treatment of chronic migraine in adults.  In September 2014, a phase III trial was initiated and expected to complete in April 2017; in January 2018, the  estimated completion date was  June 2020 [&lt;ulink linkID="1613933" linkType="Reference"&gt;1613933&lt;/ulink&gt;], [&lt;ulink linkID="1593277" linkType="Reference"&gt;1593277&lt;/ulink&gt;]. The institute is also developing the drug for  the potential treatment of muscle hypertonia. In September 2014, a phase III study was initiated and expected to complete in January 2016  [&lt;ulink linkID="1725009" linkType="Reference"&gt;1725009&lt;/ulink&gt;], [&lt;ulink linkID="1623884" linkType="Reference"&gt;1623884&lt;/ulink&gt;]; by November 2015, recruitment was finished and the trial was ongoing. In September 2016,  the trial was completed   [&lt;ulink linkID="1725009" linkType="Reference"&gt;1725009&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In September 2014, a multi-center, randomized, placebo-controlled,  double-blind, phase III study (&lt;ulink linkID="215061" linkType="Protocol"&gt;NCT02280083&lt;/ulink&gt;; HengLi002; CTR20131191; CTS1230) was initiated  to assess the efficacy and safety of the drug in chinese patients (n = 180) with post-stroke upper limb spasticity. At that time, the study was expected to complete in January 2016 [&lt;ulink linkID="1623884" linkType="Reference"&gt;1623884&lt;/ulink&gt;]. By November 2015, recruitment was finished and the trial was ongoing. In September 2016,  the trial was completed  [&lt;ulink linkID="1725009" linkType="Reference"&gt;1725009&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2012, a clinical trial application was filed in China for chronic migraine in adults; in July 2013, the application was approved [&lt;ulink linkID="1593276" linkType="Reference"&gt;1593276&lt;/ulink&gt;]. In August 2014, the institute was planning to initiate a randomized, double-blind, parallel-group, phase III trial (&lt;ulink linkID="212749" linkType="Protocol"&gt;CTR20131192&lt;/ulink&gt;; CTS1238) to evaluate the safety and efficacy of botulinum toxin A in  adults (expected n = 288) with chronic migraine [&lt;ulink linkID="1593277" linkType="Reference"&gt;1593277&lt;/ulink&gt;]. In September 2014, the trial (&lt;ulink linkID="215877" linkType="Protocol"&gt;NCT02291380&lt;/ulink&gt;; HengLi003) was initiated and was expected to complete in April 2017. In January 2018, the  estimated completion date was  June 2020 [&lt;ulink linkID="1613933" linkType="Reference"&gt;1613933&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2239">Blepharospasm</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-31T00:00:00.000Z</StatusDate><Source id="1312309" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="358">Muscle spasm</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-31T00:00:00.000Z</StatusDate><Source id="1312309" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2481">Strabismus</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-31T00:00:00.000Z</StatusDate><Source id="1312309" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1613933" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-02T00:00:00.000Z</StatusDate><Source id="1725009" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2481">Strabismus</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-31T00:00:00.000Z</StatusDate><Source id="1317187" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2239">Blepharospasm</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-31T00:00:00.000Z</StatusDate><Source id="1317187" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="358">Muscle spasm</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-31T00:00:00.000Z</StatusDate><Source id="1317187" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-08-01T00:00:00.000Z</StatusDate><Source id="1593276" type="OTHER"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00042"><Name>Acetylcholine receptor</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>